Get dividends reports and income statements for BioNTech SE (BNTX)at Ally Invest. We expect BioNTech SE (BNTX Quick Quote BNTX - Free Report) to surpass expectations when it reports third-quarter 2020 results on Nov 10, before the market opens.. Germany +49 6131-9084-0 (Address of principal executive offices) It is understandable that investor optimism is growing ahead of the company’s current quarter results. SVB Leerink has a “Market Perform” rating and a $106.00 price […] BioNTech SE (NASDAQ:BNTX) went down by -3.91% from its latest closing price compared to the recent 1-year high of $131.00. BioNTech SE, which has a market valuation of $26.17 Billion as of writing, is expected to release its quarterly earnings report on Nov 10, 2020. UNDER THE SECURITIES EXCHANGE ACT OF 1934. There are no Income Statements available at this time for BioNTech SE. The company’s stock price has collected -15.29% of loss in the last five trading sessions. View the latest BNTX financial statements, income statements and financial ratios. In comparison, last year the company earned revenue of $25.79 million and had a GAAP net loss of $50.08 million. Shu expects BioNTech SE to post earnings per share (EPS) of $0.00 for the first quarter of 2021. BioNTech has 1,300 employees across 8 locations and €1.99 M in annual revenue in FY 2019. This field is either calculated as the sum of the long term debt fields or used if a company does not report debt issued and repaid separately BioNTech SE annual/quarterly net long-term debt history and growth rate from 2019 to 2020. MarketWatch.com reported 6 hours ago that BioNTech SE ADR underperforms Thursday when compared to competitors. BioNTech SE (NASDAQ:BNTX) – Equities researchers at SVB Leerink reduced their Q3 2020 earnings per share estimates for BioNTech in a research note issued on Wednesday, October 14th. BioNTech SE, whose market valuation is $26.49 Billion at the time of this writing, is expected to release its quarterly earnings report in Mar 2021. In addition, the growth of sales from quarter to quarter is recording -3.70%, hinting the company’s progress in the upcoming progress. Find the latest Net Income (Quarterly) for BioNTech SE Sponsored ADR (BNTX) BioNTech SE is expected to release its quarterly report on 05/18/2021 and quarterly earnings per share for the current quarter are estimated at $0.18 with sales reaching $353.32M over the same period.The EPS is expected to shrink by -300.50% this year, but quarterly … BioNTech SE (Translation of registrant’s name into English) An der Goldgrube 12. COMMISSION FILE NUMBER 001-39081 . BioNTech is a Germany-based biotechnology company that focuses on developing cancer therapeutics, including individualized immunotherapy, as... BNTX BioNTech SE stock 228 Based on BioNTech SE’s latest earnings release for the quarter ending June 30, the company reported a quarterly revenue of $41.76 million and GAAP net loss of $88.3 million. Get the hottest stocks to trade every day before the market opens 100% free. BioNTech SE (BNTX) Analysis. For a discussion of these and other risks and uncertainties, see BioNTech’s Quarterly Report for the Three and Nine Months Ended September 30, 2020, filed as Exhibit 99.2 to its Current Report on Form 6-K filed with the SEC on November 10, which is available on the SEC’s website at www.sec.gov. Barron’s reported 12 hours ago that Expect Treasury Yields to Start Climbing Again Soon, BCA Says. FOR THE MONTH OF MAY 2020. The company’s stock price has collected 1.52% of gains in the last five trading sessions. According to TipRanks.com, Kasimov is a 5-star analyst with an average return of 22.6% and a 56.5% success rate. The company stock has a Forward Dividend ratio of 0, while the dividend yield is 0. For a discussion of these and other risks and uncertainties, see BioNTech’s Quarterly Report for the Three and Nine Months Ended September 30, 2020, filed as Exhibit 99.2 to its Current Report on Form 6-K filed with the SEC on November 10, which is available on the SEC’s website at www.sec.gov. Investors’ optimism about the company’s current quarter earnings report is understandable. D-55131 Mainz. BioNTech SE ADR quarterly income statement. Quotes Snapshot > BNTX. Kasimov covers the Healthcare sector, focusing on stocks such as Ultragenyx … In a report released yesterday, Cory Kasimov from J.P. Morgan maintained a Hold rating on BioNTech SE (BNTX – Research Report).The company’s shares closed last Tuesday at $102.03. The present dividend yield for BNTX owners is set at 0, marking the return investors will get regardless of the company’s performance in the upcoming period. Net long-term debt can be defined as the net amount of long term debt issued and repaid. BioNTech SE ADR Quarterly stock financials by MarketWatch. BioNTech has not formally confirmed its next earnings publication date, but the company's estimated earnings date is Tuesday, March 30th, 2021 based off prior year's report dates. See insights on BioNTech including office locations, competitors, revenue, financials, executives, subsidiaries and more at Craft. In a report released today, Robert Burns from H.C. Wainwright reiterated a Hold rating on BioNTech SE (BNTX – Research Report).The company’s shares closed last Friday at $84.17. BioNTech SE (NASDAQ:BNTX) went down by -2.16% from its latest closing price compared to the recent 1-year high of $131.00. BioNTech SE (NASDAQ:BNTX) – Analysts at SVB Leerink issued their Q1 2022 EPS estimates for BioNTech in a research note issued on Thursday, February 4th. Get the hottest stocks to trade every day before the market … Biontech Se Sponsored Adr Stock Earnings Report NASDAQ:BNTX Current P/E ratio: 0.00 | Price (February 12, 2021, EOD): $117.56 (Find current average P/E ratios for all sectors below ) BNTX Upcoming Earnings (Q4): BioNTech Earnings Estimates and Actuals by Quarter 207 institutions hold shares in BioNTech SE (BNTX), with 2.85M shares held by insiders accounting for 1.18% while institutional investors hold 10.64% of the company’s shares. J.P. Morgan analyst Cory Kasimov maintained a Hold rating on BioNTech SE (BNTX – Research Report) on December 8.The company’s shares closed last Tuesday at $111.20. For a discussion of these and other risks and uncertainties, see BioNTech’s Quarterly Report for the Three and Nine Months Ended September 30, 2020, filed as Exhibit 99.2 to its Current Report on Form 6-K filed with the SEC on November 10, which is available on the SEC’s website at www.sec.gov. BioNTech SE said Tuesday manufacturing plans foresee production of up to 1.3 billion doses next year of the Covid-19 vaccine it is developing with Pfizer Inc. ... Quarterly Annual. Shareholders will be ecstatic, with their stake up 21% over the past week following BioNTech SE's (NASDAQ:BNTX) latest quarterly results.Revenues of €67m crushed expectations, although expenses also blew out, with the company reporting a statutory loss per share of €0.88, 114% bigger than analysts expected. SVB Leerink analyst D. Graybosch expects that the company will post earnings of $6.76 per share for the quarter. REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a‑16 OR 15d‑16. The shares outstanding are 238.67M, and float is at 223.06M with Short Float at 2.10%. According to TipRanks.com, Kasimov is a 5-star analyst with an average return of 22.5% and a 57.4% success rate. According to TipRanks.com, Burns is a 4-star analyst with an average return of 16.9% and a 56.5% success rate. View BNTX financial statements in full, including balance sheets and ratios. Net Income (Quarterly) is a widely used stock evaluation measure.
Inga Lindström Feuer Unterm Dach Besetzung, Bernhard Schir Lebenslauf, Gastronomie Vaihingen Enz, Eid Prayer Timing, Etv Basketball Instagram, Wandern Ettlingen Wattkopf, Forxiga 10 Mg, Handball-wm: Deutschland - Spanien Ergebnis, Bulgarische Nachnamen Mit Z, Hummel Authentic 2020, Stockholm, Wisconsin Population, Cvo Hamburg Lehrer,